CancerPOP at ASH2018

CancerPOP is honored to have contributed to 10 abstracts being presented at the 2018 American Society of Hematology Annual Meeting in San Diego on December 1-4, 2018. The presentations are in partnership with Cellworks Group Inc. and based on the use of a genomics-informed Computational Biology Modeling technology (CBM) to predict drug response within specific cancer tumors.

The Founder of CancerPOP, Christopher Cogle said, "The combination of genetic testing, computer analysis and clinical oncology experience is proving to be a powerful new way of finding the right treatments for patients. At CancerPOP, our mission is to make this combination available to help cancer patients do everything they can."

CancerPOP is a global Personalized Medicine company that performs genetic testing and precision oncology consulting for cancer patients and their doctors. For more information, please visit http://www.cancerpop.com.

Follow CancerPOP on Facebook: @PrecisionOncologyProgram,  Twitter: @OncologyProgram, Instagram: @cancerpop_precisiononcology, and LinkedIN: @CancerPOP

CancerPOP will be part of the following abstract presentations:

Note: All presentations will take place at the San Diego Convention Center in Hall GH 

Predictive Analysis on Prognostic Impact of Monosomy 7 in AML and Identified Therapy Options for This Cohort
Date & Time:  Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Abstract: 1539
Presenter:  Shireen Vali

WT1 and BCORL1 Identified by Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)
Date & Time:  Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Abstract:  1538
Presenter:  Shireen Vali

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study
Date & Time:  Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Poster Session:  617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Abstract:  1540
Presenter:  Shireen Vali

Computational Modeling of Multiple Myeloma Patient Genomic Signatures to Predict Treatment Outcome
Date & Time:  Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Abstract:  1911
Presenter:  Aneel Paulus

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study
Date & Time:  Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session:  617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I
Abstract: 1541
Presenter:  Shireen Vali

Clinical Validation of Treatment Response Predictions Using a Genomics Driven Computational Biology Modeling Multiple Myeloma Algorithm
Date & Time:  Saturday, December 1, 2018 from 6:15 PM-8:15 PM
Session:  651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Abstract: 1893
Presenter:  Justin King

Analysis of the Evolving MDS/AML Clones to Identify Resistance Mechanisms and Predict New Therapy Options at Relapse Using Computational Biology Modeling: Case-Studies from iCare1 Clinical Study
Date & Time:  Sunday, December 2, 2018 from 6:00 PM-8:00 PM
Session:  637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Abstract:  3086
Presenter:  Shireen Vali

Azacitidine Response Prediction in MDS Patients with NGS Data Using a Computational Biology Modeling (CBM) Based Clinical Decision Support System
Date & Time:  Sunday, December 2, 2018 from 6:00 PM-8:00 PM
Poster Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster II
Abstract:  3087 
Presenter: Lubomir Minarik

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modeling of Genomics and Proteomics
Date & Time:  Sunday, December 2, 2018 from 6:00 PM-8:00 PM
Session:  652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Abstract:  3193
Presenter:  Shireen Vali

AraC-Daunorubicin-Etoposide (ADE) Response Prediction in Pediatric AML Patients Using a Computational Biology Modeling (CBM) Based Precision Medicine Workflow
Date & Time:  Monday, December 3, 2018 from 6:00 PM-8:00 PM
Session:  615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Poster III
Abstract:  4034
Presenter:  Shireen Vali

Matthew Matassa